Morgan Stanley Maintains Overweight on Tenaya Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Tenaya Therapeutics (NASDAQ:TNYA) and raises the price target from $13 to $14.
August 10, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Tenaya Therapeutics and raises the price target from $13 to $14.
The news is directly related to Tenaya Therapeutics. Morgan Stanley's decision to maintain an Overweight rating and raise the price target indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100